Your browser doesn't support javascript.
loading
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.
Ghesquieres, H; Chevrier, M; Laadhari, M; Chinot, O; Choquet, S; Moluçon-Chabrot, C; Beauchesne, P; Gressin, R; Morschhauser, F; Schmitt, A; Gyan, E; Hoang-Xuan, K; Nicolas-Virelizier, E; Cassoux, N; Touitou, V; Le Garff-Tavernier, M; Savignoni, A; Turbiez, I; Soumelis, V; Houillier, C; Soussain, C.
Afiliación
  • Ghesquieres H; Department of Hematology, Centre Hospitalier Lyon Sud, Université Claude Bernard Lyon 1, Pierre-Bénite; Department of Hematology, Centre Léon Bérard, Université Claude Bernard Lyon 1, Lyon.
  • Chevrier M; Departments of Biostatistics, Aix Marseille University, AP-HM, Marseille.
  • Laadhari M; Radiology, Institut Curie, Saint-Cloud, Aix Marseille University, AP-HM, Marseille.
  • Chinot O; Department of Neuro-Oncology, Hôpital de la Timone, Aix Marseille University, AP-HM, Marseille.
  • Choquet S; Department of Hematology, Groupe Hospitalier Pitié-Salpêtrière, Université Pierre et Marie Curie, Paris.
  • Moluçon-Chabrot C; Department of Hematology, CHU Clermont Ferrand, Clermond Ferrand.
  • Beauchesne P; Department of Neuro-Oncology, CHU Nancy, Nancy.
  • Gressin R; Department of Hematology, CHU La Tronche, Grenoble.
  • Morschhauser F; Department of Hematology, Centre Hospitalier Universitaire, Université de Lille, Lille.
  • Schmitt A; Department of Hematology, Institut Bergonié, Bordeaux.
  • Gyan E; Department of Hematology and Cellular Therapy, CIC INSERM U1517, Centre Hospitalier Universitaire, Université de Tours, Tours.
  • Hoang-Xuan K; Department of Neurology 2 Mazarin, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne University, IHU, ICM, Paris.
  • Nicolas-Virelizier E; Department of Hematology, Centre Léon Bérard, Université Claude Bernard Lyon 1, Lyon.
  • Cassoux N; Department of Ophthalmology, Institut Curie - Site Paris, Paris.
  • Touitou V; Department of Ophthalmology, Hôpital Pitié Salpetrière, Université Pierre et Marie Curie, Paris.
  • Le Garff-Tavernier M; Groupe Hospitalier Pitié-Salpétrière, Biological Hematology, Paris, France; Paris University Sorbonne UPMC, INSERM UMRS 1138, Paris.
  • Savignoni A; Departments of Biostatistics, Aix Marseille University, AP-HM, Marseille.
  • Turbiez I; Departments of Biostatistics, Aix Marseille University, AP-HM, Marseille.
  • Soumelis V; Clinical Immunology Laboratory, Department of Biopathology, INSERM U932, Immunity and Cancer, Institut Curie, Paris.
  • Houillier C; Department of Neurology 2 Mazarin, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne University, IHU, ICM, Paris.
  • Soussain C; Department of Hematology, Institut Curie, Saint-Cloud, France. Electronic address: carole.sousain@curie.fr.
Ann Oncol ; 30(4): 621-628, 2019 04 01.
Article en En | MEDLINE | ID: mdl-30698644
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células B Grandes Difuso / Neoplasias del Sistema Nervioso Central / Linfoma Intraocular / Rituximab / Lenalidomida Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células B Grandes Difuso / Neoplasias del Sistema Nervioso Central / Linfoma Intraocular / Rituximab / Lenalidomida Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article Pais de publicación: Reino Unido